2024-01-22 17:36:05 ET
More on EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal
- Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain
- Countdown To Clarity: EyePoint's December Data Delivery
- EyePoint Pharmaceuticals prices upsized $200 million stock offering
- EyePoint commences $175M stock offering to advance wet AMD therapy into late-stage
Read the full article on Seeking Alpha
For further details see:
JP Morgan starts EyePoint at overweight, cites eye drug potential